secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001104659-26-000432
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia reports positive Phase 1b results for DA-1726; 9.1% weight loss by Day 54
--------------------------------------------------------------------------------

- Statistically significant 9.1% weight loss (21.2 lbs) and 9.8 cm waist reduction by Day 54 in Phase 1b MAD cohort.
- Liver stiffness reduced 23.7% by Day 54 via VCTE, indicating direct hepatic effect.
- Fasted glucose improved 12.3 mg/dL from baseline of 105.3 mg/dL; prediabetic subject HbA1c dropped from 6.0% to 5.5%.
- No treatment-related discontinuations; GI events mild to moderate.
- Plans 16-week titration studies to 48 mg and 64 mg; results expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926000432/0001104659-26-000432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926000432/tm2528002d7_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-000432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer